logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11872226 B1

PDFFull Text
Date of Patent:
Jan. 16, 2024

Filed:

Feb. 07, 2020

N-benzyl-2-phenoxybenzamide derivatives as prostaglandin e2 (pge2) receptors modulators

Applicant:

Medibiofarma, S.l., Navarra, ES;

Inventors:

Julio Castro Palomino Laria, Barcelona, ES;

Juan Camacho Gómez, Barcelona, ES;

Rodolfo Rodríguez Iglesias, Navarra, ES;

Irene Velilla Martínez, Navarra, ES;

Assignee:

MEDIBIOFARMA, S.L., Navarra, ES;

Attorney:

McKee, Voorhees & Sease, PLC

Primary Examiner:

Marcos L Sznaidman

Int. Cl.
CPC ...
A61K 31/505 (2006.01); A61K 31/195 (2006.01); A61K 31/277 (2006.01); A61K 31/341 (2006.01); A61K 31/381 (2006.01); A61K 31/415 (2006.01); A61K 31/4418 (2006.01); C07C 233/76 (2006.01); C07C 255/59 (2006.01); C07D 213/56 (2006.01); C07D 231/12 (2006.01); C07D 239/26 (2006.01); C07D 307/58 (2006.01); C07D 333/24 (2006.01);
U.S. Cl.
CPC ...
A61K 31/505 (2013.01); A61K 31/195 (2013.01); A61K 31/277 (2013.01); A61K 31/341 (2013.01); A61K 31/381 (2013.01); A61K 31/415 (2013.01); A61K 31/4418 (2013.01); C07C 233/76 (2013.01); C07C 255/59 (2013.01); C07D 213/56 (2013.01); C07D 231/12 (2013.01); C07D 239/26 (2013.01); C07D 307/58 (2013.01); C07D 333/24 (2013.01);
Abstract

The present invention relates to novel, optionally substituted, N-benzyl-2-phenoxybenzamide derivatives of formula (I), as modulators of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2), to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use in the treatment of pathological conditions, disorders or diseases that can improve by modulation of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2) such as cancer disease, pain, inflammation, neurodegenerative diseases and kidney diseases.

Find Patent Forward Citations

Loading…